EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment

Nuria García-Agua Soler, Lucía García Trujillo, Antonio J García-Ruiz

Revista de Neurología · 23.07.2025 · 80 (6)

DOI: 10.31083/rn33482 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista de Neurología, online erschienen am 23.07.2025. Verfasst von Nuria García-Agua Soler und 2 weiteren Autor:innen. Beteiligte Einrichtung: Economía de la Salud y Uso Racional de Medicamentos, Departamento de Farmacología, Facultad de Medicina, 29010 Málaga, España. Hauptthemen laut MEDLINE: Parkinson Disease, Antiparkinson Agents, Quality of Life. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

As Parkinson’s disease progresses, symptoms develop that make it more difficult to control, either because of the presence of fluctuations despite adequate oral treatment, or because of the adverse effects caused by the continued use of levodopa, considered the gold standard. At this point in the course of the disease, there are different therapeutic alternatives that provide more continuous dopaminergic stimulation and help to improve this symptomatology: deep brain stimulation (Medtronic®: Percept™ Primary Cell (PC), Percept™ ReChargable (RC)), intestinal gel Levodopa/Carbidopa (Duodopa®) o Levodopa/Carbidopa/Entacapona (Lecigon®), as well as subcutaneous infusion of foslevodopa/foscarbidopa (Foslevodopa®) and continuous infusion of apomorphine (Dacepton®, Apo-Go®).

Objective

Pharmacoeconomic study of the different therapies for treating advanced Parkinson’s disease in Spain. Patients and Methods: Based on a Markov model, the efficacy and costs of these therapies were compared, measuring life years gained (LYG) and quality-adjusted life years (QALY).

Results

Dacepton® (apomorphine) is the most cost-effective option with a cost of 20,782€/QALY (1€ = 1.0815 USD, 2025), compared to three times or more for the other therapies with Lecigon® (levodopa/carbidopa/entacapone) being the least cost-effective with a cost of 104,000€/QALY. Deep brain stimulation (DBS) and Duodopa® also proved to be effective options, but more costly than Dacepton®.

Conclusions

These results provide additional information on the efficiency of treatments that should inform decision-making in the management of advanced Parkinson’s disease, thus enabling better resource management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Parkinson DiseaseAntiparkinson AgentsQuality of LifeHumansLevodopaDeep Brain StimulationCarbidopaApomorphineDrug CombinationsMarkov ChainsQuality-Adjusted Life YearsCost-Benefit AnalysisSpain

Stichwörter der Autor:innen

Parkinson diseasecost-benefit analysisquality-adjusted life years

Substanzen

LevodopaAntiparkinson AgentsCarbidopaApomorphineDrug Combinationscarbidopa, levodopa drug combination

Autor:innen und Institutionen

  • Economía de la Salud y Uso Racional de Medicamentos, Departamento de Farmacología, Facultad de Medicina, 29010 Málaga, España.
  • Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, 29016 Málaga, España.
  • Servicio de Neurología, Hospital Regional Universitario de Málaga, 29010 Málaga, España.

Zitieren

APA

García-Agua Soler, N., García Trujillo, L., & García-Ruiz, A. J. (2025). Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment. Revista de Neurología, 80(6). https://doi.org/10.31083/rn33482

Vancouver

García-Agua Soler N, García Trujillo L, García-Ruiz AJ. Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment. Revista de Neurología. 2025;80(6). doi:10.31083/rn33482

BibTeX
@article{GarcaAguaSoler2025,
  author = {García-Agua Soler, Nuria and García Trujillo, Lucía and García-Ruiz, Antonio J},
  title = {Cost of Quality of Life in Advanced Parkinson’s Disease: Efficient Strategies for Disease Assessment},
  journal = {Revista de Neurología},
  year = {2025},
  volume = {80},
  number = {6},
  doi = {10.31083/rn33482}
}
Kostenlos starten →